Your AI-Trained Oncology Knowledge Connection!
Updated findings from the phase 3 MONALESSA-3 trial identified a significant overall survival benefit among postmenopausal patients with hormone receptor–positive, HER2-negative breast cancer who were treated with ribociclib and fulvestrant vs matched placebo.
Findings from the phase 3 DESTINY-Breast03 trial have led to the FDA approval of fam-trastuzumab deruxtecan-nxki for the treatment of patients with unresectable or metastatic HER2-positive breast cancer.
Sam Klempner, MD, spoke about how clinicians exploring use of ctDNA in gastrointestinal cancers may inform their research with results from other tumor types.
Nina Shah, MD, spoke about analyzing correlates of complete response in patients with relapsed/refractory multiple myeloma who were treated with idecabtagene vicleucel.
Investigators have identified an association between the diagnosis and care of older patients with multiple myeloma and substantial financial burden on Medicare.
The results of the phase 3 TOPAZ-1 trial led to the priority review of durvalumab plus chemotherapy in patients with locally advanced biliary tract cancer.
Despite its use in a population with broad characteristics and high-risk features, a real-world outcome analysis demonstrated brexucabtagene autoleucel’s feasibility and efficacy in those with mantle cell lymphoma.
Gennady Bratslavsky, MD, at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, spoke about which research in renal cell carcinoma has the greatest potential for clinical impact.
An ongoing trial assessing neoadjuvant mirvetuximab soravtansine plus carboplatin in advanced folate receptor α–positive ovarian was reviewed by Jhalak Dholakia, MD, at The Society of Gynecologic Oncology 2022 Annual Meeting on Women’s Cancer.
The FDA granted priority review to a supplemental new drug application for darolutamide plus docetaxel for the treatment of metastatic hormone-sensitive prostate cancer.
Plans to resubmit a biologics license application for toripalimab as treatment of advanced recurrent or metastatic nasopharyngeal carcinoma have been made for midsummer 2022 following receipt of a complete response letter from the FDA.
Patients with persistent, recurrent or metastatic cervical cancer whose tumors express PD-L1 can receive treatment with pembrolizumab plus chemotherapy with or without bevacizumab following approval by the European Commission.
Ira Winer, MD, PhD, FACOG, spoke about future directions of nemvaleukin alfa plus pembrolizumab for patients with pretreated platinum resistant ovarian cancer.
In a conversation with CancerNetwork®, Nicolas Girard, MD, highlighted directions of future research with nivolumab and chemotherapy in patients with resectable non–small cell lung cancer.
Surufatinib, a treatment for patients with pancreatic and extra-pancreatic neuroendocrine tumors, received a complete response letter from the FDA.
Patients with N0 to N1 nasopharyngeal carcinoma who received upper-neck radiation vs whole-neck radiation saw similar regional control with less radiation toxicity.
At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Daniel P. Petrylak, MD, reflects upon mentorship during his training to become an oncologist.
Trastuzumab deruxtecan has been granted breakthrough therapy designation by the FDA for the treatment for HER2-low metastatic breast cancer.
A qualitative analysis identified 4 themes that could be improved upon to help with symptom management in patients with head and neck cancer.
Gregory Riely, MD, PhD, and Tarek Mekhail, MD, detailed the use of mobocertinib of platinum-pretreated patients with metastatic non–small cell lung cancer.
At SGO 2022, Catherine Watson, MD, spoke about the 2 arms of a randomized education trial presented at the conference.
In an interview with CancerNetwork®, Nicolas Girard, MD, discussed the rationale for assessing nivolumab and chemotherapy in resectable non–small cell lung cancer and the design of the phase 3 CheckMate 816 trial.
Patients with TP53-mutant acute myeloid leukemia experienced poor overall survival following treatment with hematopoietic stem cell transplantation, suggesting a need for more careful patient selection, further clinical trial enrollment, and personalized treatment strategies.
Matthew Krebs, MB, PhD spoke about efficacy of subcutaneous amivantamab observed in the phase 1 PALOMA trial for patients with solid tumors.
Patients with platinum-resistant ovarian cancer may benefit from treatment with ofranergene obadenovec, which received fast track designation from the FDA.
Response to idecabtagene vicleucel for patients with pretreated multiple myeloma did not appear to be influenced by baseline body mass index.
JSP191 plus fludarabine and low-dose total body radiation to target CD117 was a safe strategy to induce facilitation of full donor myeloid chimerism and clear minimal residual disease in older patients with myelodysplastic syndrome and acute myeloid leukemia receiving non-myeloablative allogenic hematopoietic cell transplantation.
Stéphane Champiat, MD, PhD, spoke about the reasoning behind using the IL-2/IL-15 superagonist SOT101 and where the research is heading for patients with solid tumors.
Frederick Lock, MD, spoke about clinicians can best utilize the treatment of axicabtagene ciloleucel for patients with large B-cell lymphoma.
Investigators observed low enrollment of Black patients on CAR T-cell therapy clinical trials that supported FDA decisions in hematologic malignancies, especially in multiple myeloma.
